News
Previa Medical raises €2.1 million for AI solution to prevent sepsis
Previa Medical, a deeptech start-up specialized in developing predictive medical devices for alerting healthcare providers to the risk of potential complications, today announces it has raised €2.1 million ($2.2M) in seed funding for SEPSI-SCORE©, a specialist...
Novel Hydrogen transport and storage technology developer HySilabs raises 13€ million in its series A
HySiLabs today announced a EUR 13 million Series A financing led by Equinor Ventures, and joined by the European Innovation Council Fund, EDP Ventures and PLD Automobile, with the support of historical investors Kreaxi, Région Sud Investissement and CAAP Création. The...
Amolyt Pharma annonces research agreement and licensing option with XOMA
Amolyt Pharma (“Amolyt,” “Amolyt Pharma” or the “Company”), a global company specialized in developing innovative therapies for rare endocrine and related diseases, today announced that the Company has entered into a research agreement and licensing option with XOMA...
Amolyt Pharma announces $ 138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Amolyt plans to use the proceeds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly. Complete press...
OREGA Biotech enters into an Exclusive License Agreement with Genmab for a novel immuno-oncology antibody program
OREGA Biotech announces today an exclusive license agreement under which OREGA Biotech grants Genmab full, worldwide rights to its first-in-class immuno-oncology antibody program against a novel and undisclosed target. This license agreement results from a fruitful...
Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from the second patient cohort in its Phase 2a clinical proof of concept trial of AZP-3601, a PTH1 receptor...
Ciliatech presents groundbreaking concept in glaucoma implants, first to bypass opening anterior eye chamber
Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, named CID (Cilio-scleral Inter-positioning Device), today announces that the interim results of a 12-month follow-up study on its groundbreaking CID concept show...
Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in Patients with Hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive efficacy and safety data from the first cohort of its ongoing Phase 2a study of AZP-3601 in patients with...
Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced the acceptance of a late-breaking oral presentation and an additional poster presentation, including Phase 2a data for AZP-3601, its...
US EPA about to approve Amoéba’s biocide for use in closed cooling systems
AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, informs that the United States Environmental Protection...